The S&P/ASX Small Ordinaries closed at 3,830.80, down 2.40 points (0.063%) today, but up 122.60 points (3.31%) over the past five days.
With the market consolidating recent gains, here are some key small-cap company updates from this morning.
Asian Battery Metals PLC (ASX:AZ9) says Phase 3 drilling at the Oval copper-nickel-platinum group elements discovery at the 100%-owned Yambat Project in Western Mongolia has expanded known mineralisation and confirmed new high-conductance electromagnetic plates for follow-up, supporting the view of a significant magmatic system with both high-grade massive sulphide and bulk-tonnage potential.
American Uranium Ltd (ASX:AMU, OTC:GTRIF) has completed requirements to change its cross-trade ticker on the OTCID Market in North America; shares now quote under “AMUIF”.
European Lithium Ltd (ASX:EUR, OTCQB:EULIF) reports Critical Metals Corp (Nasdaq: CRML) sold 3 million CRML shares off-market to a single United States institutional investor at US$7 per share, raising US$21 million (approximately A$31.75 million) in net proceeds to EUR. Executive chairman Tony Sage said, “This transaction again highlights the value of the Company's holding in CRML. The remaining 60 million shares held in CRML, using the $US11.50 closing price on the Nasdaq yesterday, values the Company’s holding at approximately $US689M ($A1,061m), which is well above the current market capitalisation of EUR. The Company’s holding in CRML equates to A$0.73c per EUR share.”
Greatland Resources Ltd (AIM:GGP, OTC:GRLGF, ASX:GGP) posted preliminary September-quarter production of 80,890 ounces gold and 3,366 t copper, sales of 82,199 ounces gold and 3,277 t copper, cash of A$750 million and no debt; fiscal year 2026 guidance remains 260,000–310,000 ounces gold at an all-in sustaining cost of A$2,400–A$2,800 per ounce.
Krakatoa Resources Ltd (ASX:KTA) has two diamond rigs advancing a 7,000–10,000 metre maiden program at Zopkhito in Georgia; adit core sampling is imminent as it targets conversion of a historical foreign resource [1] of 225,000 tonnes at 11.6% antimony and 7.1 million tonnes at 3.7 g/t gold; initial assays are expected in late fourth quarter 2025.
Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) released final Phase I data for HMBD-002 across 48 heavily pre-treated metastatic cancer patients in the United States, showing a favourable safety profile up to 1,400 milligrams per week (monotherapy and with Keytruda®), with planning for a Phase II efficacy trial in calendar year 2026.